Advances in non-surgical management of primary liver cancer

被引:56
作者
Chen, Xiao [1 ,2 ]
Liu, Hai-Peng [1 ,2 ]
Li, Mei [1 ,2 ]
Qiao, Liang [3 ,4 ]
机构
[1] Lanzhou Univ, Hosp 2, Dept Gen Surg, Lanzhou 730030, Gansu, Peoples R China
[2] Key Lab Digest Syst Tumors Gansu Prov, Lanzhou 730030, Gansu, Peoples R China
[3] Univ Sydney, Dept Med, Westmead Millennium Inst, Storr Liver Unit, Westmead, NSW 2145, Australia
[4] Univ Sydney, Western Clin Sch, Westmead, NSW 2145, Australia
关键词
Ablation therapy; Biotherapy; Hepatocellular carcinoma; Hormonal therapy; Percutaneous ethanol injection; Percutaneous microwave coagulation therapy; Radiofrequency ablation; Radiotherapy; Transcatheter arterial chemoembolization; Chemotherapy; UNRESECTABLE HEPATOCELLULAR-CARCINOMA; INTENSITY FOCUSED ULTRASOUND; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; 3-DIMENSIONAL CONFORMAL RADIOTHERAPY; PERCUTANEOUS ETHANOL INJECTION; TERM-FOLLOW-UP; PHASE-II; TRANSARTERIAL CHEMOEMBOLIZATION; PROGNOSTIC-FACTORS; SAFE THERAPY;
D O I
10.3748/wjg.v20.i44.16630
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer-related death worldwide. There have been great improvements in the diagnosis and treatment of HCC in recent years, but the problems, including difficult diagnosis at early stage, quick progression, and poor prognosis remain unsolved. Surgical resection is the mainstay of the treatment for HCC. However, 70%-80% of HCC patients are diagnosed at an advanced stage when most are ineligible for potentially curative therapies such as surgical resection and liver transplantation. In recent years, non-surgical management for unrespectable HCC, such as percutaneous ethanol injection, percutaneous microwave coagulation therapy, percutaneous radiofrequency ablation, transcatheter arterial chemoembolization, radiotherapy, chemotherapy, bio-therapy, and hormonal therapy have been developed. These therapeutic options, either alone or in combination, have been shown to control tumor growth, prolong survival time, and improve quality of life to some extent. This review covers the current status and progress of non-surgical management for HCC. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
引用
收藏
页码:16630 / 16638
页数:9
相关论文
共 71 条
[1]   Modes of resistance to anti-angiogenic therapy [J].
Bergers, Gabriele ;
Hanahan, Douglas .
NATURE REVIEWS CANCER, 2008, 8 (08) :592-603
[2]   Endolymphatic immunotherapy in inoperable hepatocellular carcinoma [J].
Bertelli, R. ;
Neri, F. ;
Tsivian, M. ;
Ruhrman, N. ;
Cavallari, G. ;
Beltempo, P. ;
Puviani, L. ;
DeVinci, C. ;
Pizza, G. ;
Nardo, B. .
TRANSPLANTATION PROCEEDINGS, 2008, 40 (06) :1913-1915
[3]   Receptor mechanisms mediating non-genomic actions of sex steroids [J].
Boonyaratanakornkit, Viroj ;
Edwards, Dean P. .
SEMINARS IN REPRODUCTIVE MEDICINE, 2007, 25 (03) :139-153
[4]   Epidemiology of primary liver cancer [J].
Bosch, FX ;
Ribes, J ;
Borràs, J .
SEMINARS IN LIVER DISEASE, 1999, 19 (03) :271-285
[5]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[6]   Management of Hepatocellular Carcinoma: An Update [J].
Bruix, Jordi ;
Sherman, Morris .
HEPATOLOGY, 2011, 53 (03) :1020-1022
[7]  
Chen Wan-qing, 2012, Zhonghua Yu Fang Yi Xue Za Zhi, V46, P581
[8]   High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial [J].
Chow, PKH ;
Tai, BC ;
Tan, CK ;
Machin, D ;
Win, KM ;
Johnson, PJ ;
Soo, KC .
HEPATOLOGY, 2002, 36 (05) :1221-1226
[9]   Management of hepatocellular carcinoma [J].
Cormier, Janice N. ;
Thomas, K. Tyson ;
Chari, Ravi S. ;
Pinson, C. Wright .
JOURNAL OF GASTROINTESTINAL SURGERY, 2006, 10 (05) :761-780
[10]  
Dancey JE, 2000, J NUCL MED, V41, P1673